1) Achanta S, Sewell A, Ritchey JW, Broaddus K, Bourne DW, Clarke CR, Maxwell LK. Anatomical and physiological basis for the allometric scaling of cisplatin clearance in dogs. J Vet Pharmacol Ther 39, 224-236, 2016.
2) Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16, 1310-1317, 1998.
3) Bao YW, Yuan Y, Chen JH, Lin WQ. Kidney disease models: tools to identify mechanisms and potential therapeutic targets. Zool Res 39, 72-86, 2018.
4) Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 121, 4210-4221, 2011.
5) Bourbouze R, Baumann FC, Bonvalet JP, Farman N. Distribution of N-acetyl-beta-D- glucosaminidase isoenzymes along the rabbit nephron. Kidney Int 25, 636–642, 1984.
6) Callens AJ, Bartges JW. Urinalysis. Vet Clin North Am Small Anim Pract 45, 621-637, 2015.
7) Chew DJ, Dibartola SP, Schenck PA. Canine and Feline Nephrology and Urology. 2nd ed, Saunders, Philadelphia. pp. 63-92, 2010.
8) Ciccarelli RB, Solomon MJ, Varshavsky A, Lippard SJ. In vivo effects of cis- and trans- diamminedichloroplatinum (II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry 24, 7533-7540, 1985.
9) Da Y, Akalya K, Murali T, Vathsala A, Tan CS, Low S, Lim HN, Teo BW, Lau T, Ong L, Chua HR. Serial quantification of urinary protein biomarkers to predict drug-induced acute kidney injury. Curr Drug Metab 20, 656-664, 2019.
10) D'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int 63, 809-825, 2003.
11) Daugaard G, Abildgaard U, Holstein-Rathlou NH, Leyssac PP, Amtorp O, Dikhoff TG. Acute effect of cisplatin on renal hemodynamics and tubular function in dog kidneys. Ren Physiol 9, 308-316, 1986.
12) Daugaard G, Abildgaard U, Larsen S, Holstein-Rathlou NH, Amtorp O, Olesen HP, Leyssac PP. Functional and histopathological changes in dog kidneys after administration of cisplatin. Ren Physiol 10, 54-64, 1987.
13) Dentino M, Luft FC, Yum MN, Williams SD, Einhorn LH. Long term effect of cis- diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 41, 1274-1281, 1978.
14) Du J, Cao X, Zou L, Chen Y, Guo J, Chen Z, Hu S, Zheng Z. MicroRNA-21 and risk of severe acute kidney injury and poor outcomes after adult cardiac surgery. PLoS One 8, 2013.
15) Elliott J, Cowgill L. Diagnostic algorithms for grading of acute kidney injury and staging the chronic kidney disease patient. In: BSAVA manual of canine and feline nephrology and urology. 3rd ed. Elliott J, Grauer GF. BSAVA, Gloucester. pp. 151-160, 2017.
16) Final conclusions on the pilot joint EMEA/ FDA VXDS experience on Qualification of nephrotoxicity biomarkers. EMEA, 2009.
17) Fujita H, Narita T, Morii T, Shimotomai T, Yoshioka N, Kakei M, Ito S. Increased urinary excretion of N-acetylglucosaminidase in subjects with impaired glucose tolerance. Ren Fail 24, 69-75, 2002.
18) Goto F, Watanabe I. Calcium entry blocker nicardipine inhibits sodium and inorganic phosphate reabsorption independent of renal circulation in dogs. J Anesth 6, 153-160, 1992.
19) Haase M, Haase-Fielitz A, Bellomo R, Mertens PR. Neutrophil gelatinase-associated lipocalin as a marker of acute renal disease. Curr Opin Hematol 18, 11-18, 2011.
20) Hardie EM, Page RL, Williams PL, Fischer WD. Effect of time of cisplatin administration on its toxicity and pharmacokinetics in dogs. Am J Vet Res 52, 1821-1825, 1991.
21) Hsu CY, Ordoñez JD, Chertow GM, Fan D, McCulloch CE, Go AS. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 74, 101-107, 2008.
22) Ichii O, Ohta H, Horino T, Nakamura T, Hosotani M, Mizoguchi T, Morishita K, Nakamura K, Hoshino Y, Takagi S, Sasaki N, Takiguchi M, Sato R, Oyamada K, Kon Y. Urinary exosome-derived microRNAs reflecting the changes of renal function and histopathology in dogs. Sci Rep 7, 1-11, 2017.
23) Ichii O, Ohta H, Horino T, Nakamura T, Hosotani M, Mizoguchi T, Morishita K, Nakamura K, Sasaki N, Takiguchi M, Sato R, Oyamada K, Elewa YHA, Kon Y. Urinary Exosome-Derived microRNAs Reflecting the Changes in Renal Function in Cats. Front Vet Sci 5, 1-13, 2018.
24) Ichii O, Otsuka-Kanazawa S, Horino T, Kimura J, Nakamura T, Matsumoto M, Toi M, Kon Y. Decreased miR-26a expression correlates with the progression of podocyte injury in autoimmune glomerulonephritis. PLoS One 9, 1-12, 2014.
25) Jacobs C, Kalman SM, Tretton M, Weiner MW. Renal handling of cis- diamminedichloroplatinum (II). Cancer Treat Rep 64, 1223-1226, 1980.
26) Kamijo-Ikemori A, Sugaya T, Ichikawa D, Hoshino S, Matsui K, Yokoyama T, Yasuda T, Hirata K, Kimura K. Urinary liver type fatty acid binding protein in diabetic nephropathy. Clin Chim Acta 424, 104-108, 2013.
27) Kohn S, Fradis M, Ben-David J, Zidan J, Robinson E. Nephrotoxicity of combined treatment with cisplatin and gentamicin in the guinea pig: glomerular injury findings. Ultrastruct Pathol 26, 371-382, 2002.
28) Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, Lin C, Socci ND, Hermida L, Fulci V, Chiaretti S, Foà R, Schliwka J, Fuchs U, Novosel A, Müller RU, Schermer B, Bissels U, Inman J, Phan Q, Chien M, Weir DB, Choksi R, De Vita G, Frezzetti D, Trompeter HI, Hornung V, Teng G, Hartmann G, Palkovits M, Di Lauro R, Wernet P, Macino G, Rogler CE, Nagle JW, Ju J, Papavasiliou FN, Benzing T, Lichter P, Tam W, Brownstein MJ, Bosio A, Borkhardt A, Russo JJ, Sander C, Zavolan M, Tuschl T. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129, 1401-1414, 2007.
29) Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD. Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol 11, 1173-1179, 2016.
30) Legatti SAM, El Dib R, Legatti E, Botan AG, Camargo SEA, Agarwal A, Barretti P, Paes AC. Acute kidney injury in cats and dogs: A proportional meta-analysis of case series studies. PLoS One 13, 2018.
31) Leonard BJ, Eccleston E, Jones D, Todd P, Walpole A. Antileukaemic and nephrotoxic properties of platinum compounds. Nature 234, 43-45, 1971.
32) Ling H, Chen H, Wei M, Meng X, Yu Y, Xie K. The effect of autophagy on inflammation cytokines in renal ischemia/reperfusion injury. Inflammation 39, 347-356, 2016.
33) Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, Pritchard J, Malpas JS, Baker AR, Kirkpatrick JA, Ayala AG, Shuster JJ, Abelson HT, Simone JV, Vietti TJ. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314, 1600-1606, 1986.
34) Lisowska-Myjak B. Serum and urinary biomarkers of acute kidney injury. Blood Purif 29, 357-365, 2010.
35) Lü Y, Han B, Yu H, Cui Z, Li Z, Wang J. Berberine regulates the microRNA-21- ITGB4-PDCD4 axis and inhibits colon cancer viability. Oncol Lett 15, 5971-5976, 2018.
36) Lulich JP, Osborne CA, O'Brien TD, Polzin DJ. Feline renal failure: questions, answers, questions. The compendium on continuing education for the practicing veterinarian 14, 127-152, 1992.
37) Mizumura Y, Matsumoto M, Takata M, Iida H, Sugimoto T. Case of cisplatin induced acute renal failure. Nihon Naika Gakkai Zasshi 72, 1426-1431, 1983.
38) Morita A, Numata Y, Kosugi Y, Noto A, Takeuchi N, Uchida K. Stabilities of N-acetyl- beta-D-glucosaminidase (NAG) isoenzymes in urine: advantage of NAG isoenzyme B measurement in clinical applications. Clin Chim Acta 27, 835-843, 1998.
39) Motoyoshi Y, Matsusaka T, Saito A, Pastan I, Willnow TE, Mizutani S, Ichikawa I. Megalin contributes to the early injury of proximal tubule cells during nonselective proteinuria. Kidney Int 74, 1262-1269, 2008.
40) Ogilvie GK, Krawiec DR, Gelberg HB, Twardock AR, Reschke RW, Richardson BC. Evaluation of a short-term saline diuresis protocol for the administration of cisplatin. Am J Vet Res 49, 1076-8, 1988.
41) Oliver J, MacDowell M., Lee YC. Cellular mechanisms of protein metabolism in the nephron. J Exp Med 99, 589-604, 1954.
42) Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21, 3194-3200, 2003.
43) Pavkovic M, Riefke B, Frisk AL, Gröticke I, Ellinger-Ziegelbauer H. Glomerulonephritis- induced changes in urinary and kidney microRNA profiles in rats. Toxicol Sci 145, 348-359, 2015.
44) Pavkovic M, Riefke B, Gutberlet K, Raschke M, Ellinger-Ziegelbauer H. Comparison of the mesoscale discovery and luminex multiplex platforms for measurement of urinary biomarkers in a cisplatin rat kidney injury model. J Pharmacol Toxicol Methods 69, 196- 204, 2014.
45) Pavkovic M, Robinson-Cohen C, Chua AS, Nicoara O, Cárdenas-González M, Bijol V, Ramachandran K, Hampson L, Pirmohamed M, Antoine DJ, Frendl G, Himmelfarb J, Waikar SS, Vaidya VS. Detection of drug- induced acute kidney injury in humans using urinary kim-1, mir-21, -200c, and -423. Toxicol Sci 152, 205-213, 2016.
46) Piech TL, Wycislo KL. Importance of Urinalysis. Vet Clin North Am Small Anim Pract 49, 233-245, 2019.
47) Quamme GA, de Rouffignac C. Epithelial magnesium transport and regulation by the kidney. Front Biosci 5, 694-711, 2000.
48) Reine NJ, Langston CE. Urinalysis interpretation: how to squeeze out the maximum information from a small sample. Clin Tech Small Anim Pract 20, 2-10, 2005.
49) Roberts-Thomson IC, Fon J, Uylaki W, Cummins AG, Barry S. Cells, cytokines and inflammatory bowel disease: a clinical perspective. Expert Rev Gastroenterol Hepatol 5, 703-716, 2011.
50) Rogers MS, Arumanayagam M, Fung H, Lau TK. Diurnal variation in excretion of N-acetyl-beta-glucosaminidase during pregnancy: implications for the prediction of pre-eclampsia. Gynecol Obstet Invest 47, 9-12. 1999.
51) Sasaki A, Sasaki Y, Iwama R, Shimamura S, Yabe K, Takasuna K, Ichijo T, Furuhama K, Satoh H. Comparison of renal biomarkers with glomerular filtration rate in susceptibility to the detection of gentamicin- induced acute kidney injury in dogs. J Comp Pathol 151, 264-270, 2014.
52) Sasaki D, Yamada A, Umeno H, Kurihara H, Nakatsuji S, Fujihira S, Tsubota K, Ono M, Moriguchi A, Watanabe K, Seki J. Comparison of the course of biomarker changes and kidney injury in a rat model of drug-induced acute kidney injury. Biomarkers 16, 553-566, 2011.
53) Sato K, Watanabe S, Ohtsubo A , Shoji S, Ishikawa D, Tanaka T, Nozaki K, Kondo R, Okajima M, Miura S, Tanaka J, Sakagami T, Koya T, Kagamu H, Yoshizawa H, Narita I. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. BMC Cancer 16, 222, 2016.
54) Schaefer H, Kohn B, Schweigert FJ, Raila J. Quantitative and qualitative urine protein excretion in dogs with severe inflammatory response syndrome. J Vet Intern Med 25, 1292-1297, 2011.
55) Schaeppi U, Heyman IA, Fleischman RW, Rosenkrantz H, Ilievski V, Phelan R, Cooney DA, Davis RD. cis-Dichlorodiammineplatinum (II) (NSC-119875): preclinical toxicologic evaluation of intravenous injection in dogs, monkeys and mice. Toxicol Appl Pharmacol 25, 230-241, 1973.
56) Singh AP, Junemann A, Muthuraman A, Jaggi AS, Singh N, Grover K, Dhawan R. Animal models of acute renal failure. Pharmacol Rep 64, 31-44, 2012.
57) Uechi M, Nogami Y, Terui H, Nakayama T, Ishikawa R, Wakao Y, Takahashi M. Evaluation of urinary enzymes in dogs with early renal disorder. J Vet Med Sci 56, 555- 556, 1994.
58) Vahed S, Omidi Y, Ardalan M, Samadi N. Dysregulation of urinary miR-21 and miR- 200b associated with interstitial fibrosis and tubular atrophy (IFTA) in renal transplant recipients. Clin Biochem 50, 32-39, 2017.
59) Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4, 307-320, 2005.
60) Wang G, Kwan BC, Lai FM, Chow KM, Li PK, Szeto CC. Urinary miR-21, miR-29, and miR-93: novel biomarkers of fibrosis. Am J Nephrol 36, 412-418, 2012.
61) Wang W, Li J, Zhu W, Gao C, Jiang R, Li W, Hu Q, Zhang B. MicroRNA-21 and the clinical outcomes of various carcinomas: a systematic review and meta-analysis. BMC Cancer 14, 819, 2014.
62) Yagoda A, Watson RC, Gonzalez-Vitale JC, Grabstald H, Whitmore WF. Cis- dichlorodiammineplatinum (II) in advanced bladder cancer. Cancer Treat Rep 60, 917- 923, 1976.
63) Zheng JS, Nie J, Zhu TT, Ruan HR, Wei X, Wu R. Screening of early diagnostic markers of gentamicin-induced acute kidney injury in canines. J Vet Res 63, 405-411, 2019.
64) Zhou X, Ma B, Lin Z, Qu Z, Huo Y, Wang J, Li B. Evaluation of the usefulness of novel biomarkers for drug-induced acute kidney injury in beagle dogs. Toxicol Appl Pharmacol 280, 30-35, 2014.
65) Zhou Y, Vaidya VS, Brown RP, Zhang J, Rosenzweig BA, Thompson KL, Miller TJ, Bonventre JV, Goering PL. Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. Toxicol Sci 101, 159- 170, 2008.
論文の公開元へ
